Abstract
In this article we have described clinical pharmacology and data of clinical studies of an innovational drug valsartan + sacubitril in patients with chronic heart failure (CHF). The use of supramolecular complex valsartan + sacubitril allows to elevate quality of life and improve prognosis of patients with CHF. High efficacy of valsartan+sacubitril relative to impact on composite primary end-point (cardiovascular death + hospitalization due to CHF) was demonstrated in the clinical trial PARADIGM-HF in which it was compared with angiotensin converting enzyme inhibitor enalapril. Advantages of the use of valsartan + sacubitril for the budget were demonstrated in pharmacoeconomic studies. These advantages are maximally realized at long-term administration. Cost-efficacy of the use of valsartan+sacubitril in pharmacotherapy of CHF is comparable with that of statins in the treatment of ischemic heart disease or implantation of a cardioverter-defibrillator in prevention of sudden cardiac death. Thus, introduction of the drug into practice can be expected to reduce budget expenditures.
Highlights
IV ФК по NYHA: β-адреноблокаторов, блокаторов ренин-ангиотензиновую систему (РАС) ма позволяет проводить скрининг, дифференциальную и АМКР [12, 13]
В результате международного многоцентрового двойного слепого клинического исследования с активным контролем PARADIGM-HF, в котором оценивались эффективность и безопасность препарата валсартан + сакубитрил по сравнению с ингибитором АПФ при лечении пациентов, страдающих Хроническая сердечная недостаточность (ХСН)-НФВ, получены доказательства того, что препарат позволяет значительно улучшить качество жизни и прогноз у таких больных [23]
18 лет, подписанное информированное согласие, ХСН II–IV ФК по NYHA, фракцией выброса (ФВ) левого желудочка (ЛЖ) менее 40 %, уровень BNP ≥150 пг / мл или NT-proBNP ≥600 пг / мл, или при наличии госпитализации по поводу ХСН в последние 12 мес BNP ≥100 пг / мл или NT-proBNP ≥400 пг / мл, терапия стабильными дозами ингибитора АПФ / БРА, эквивалентными не менее 10 мг / сут эналаприла
Summary
Summary In this article we have described clinical pharmacology and data of clinical studies of an innovational drug valsartan + sacubitril in patients with chronic heart failure (CHF). The use of supramolecular complex valsartan + sacubitril allows to elevate quality of life and improve prognosis of patients with CHF. Advantages of the use of valsartan + sacubitril for the budget were demonstrated in pharmacoeconomic studies. These advantages are maximally realized at long-term administration. Cost-efficacy of the use of valsartan+sacubitril in pharmacotherapy of CHF is comparable with that of statins in the treatment of ischemic heart disease or implantation of a cardioverter-defibrillator in prevention of sudden cardiac death.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
